Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da R. Suppi

Dabigatran e analisi di laboratorio
Dabigatran and laboratory tests
R. Facchinetti  |  B. Capizzi  |  B. Caruso  |  M. Negri  |  R. Suppi  |  G. Molon  |  G.C. Guidi  | 
<p>New oral anticoagulants (i.e., dabigatran, rivaroxaban, apixaban) are now&nbsp;available. In using these drugs, routine monitoring of laboratory coagulation tests is not recommended. In some&nbsp;clinical conditions, however, a laboratory evaluation of hemostatic balance may be useful. Tests suggested for&nbsp;laboratory monitoring of dabigatran treatment are thrombin time on undiluted (TT) or diluted (dTT) plasma and ecarin&nbsp;clotting time. On 30 patients taking dabigatran for non valvular atrial fibrillation, we assayed dabigatran levels by dTT,&nbsp;also performing prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and TT. In patients&nbsp;taking dabigatran etexilate 110 mg bis in die and 150 mg bis in die, dTT mean results (10<sup>th</sup>-90<sup>th</sup> percentile) were 97&nbsp;(32-152) and 94 (33-189) &mu;g/L, respectively. In dTT range from 13 to 60 &mu;g/L and &gt;60 &mu;g/L, we obtained 27% and&nbsp;58% prolonged PT, 64% and 95% prolonged APTT, and 100% and 100% prolonged TT, respectively, showing that for&nbsp;dabigatran TT is a useful screening test.</p>
Biochimica Clinica ; 39(1) 041-047
Contributi scientifici - Scientific Papers
 
Due casi di malaria diagnosticati incidentalmente con un analizzatore ematologico
Two cases of malaria incidentally diagnosed with a hematology analyzer
<p>Although the malaria infection is essentially a problem in tropical countries, it has becoming a health issue even in Western countries due to tourism and immigration. The specific diagnostic tests are ordered if a clinical suspicion is raised, but symptoms of malaria infection can be vague and easily attributed to minor febrile affections, particularly in non-endemic regions. The diagnosis of malaria cannot be dismissed to rapidly establish the appropriate treatment, avoiding harmful complications of the disease. Recently, hematological analyzers have been proposed as potentially useful tools to detect in the blood count of affected patients abnormalities that can guide a timely malaria diagnosis. We present here two cases of malaria infection in which the first diagnostic suspicion was posed on the basis of abnormal scattergrams of a hematological analyzer. The aim is to present this relatively new diagnostic opportunity, increasing the awareness of laboratorians on the possibility to raise a suspicion of malaria infection, even if specific diagnostic tests have not been ordered.</p>
Biochimica Clinica ; 36(3) 204-208
Casi Clinici - Case Report
 
Esperienza pilota di accreditamento di un centro per la diagnosi della trombosi e la sorveglianza delle terapie antitrombotiche
A pilot accreditation experience of a thrombosis center
<p>This paper describes the process of the accreditation of our Thrombosis Center by the Italian Federation of Thrombosis Centers (FCSA). The experience is reported, describing in details the organizational and clinical standard requirements and emphasizing foreseeable benefits and expectations for patients, operators, hospital, and health service.</p>
Biochimica Clinica ; 36(2) 090-097
Contributi Scientifici - Scientific Papers